{
  "abstract": "Background The effects of GLP-1 receptor agonists in patients with chronic pancreatitis (CP) and type 2 diabetes mellitus (T2DM) remain uncertain. This study evaluated whether GLP-1 receptor agonist use was associated with pancreatic, gastrointestinal, metabolic, procedural, and survival outcomes in this population.Methods This retrospective propensity score-matched cohort study used the TriNetX Collaborative Network (68 healthcare organizations). Adults with CP and T2DM receiving a GLP-1 receptor agonist were compared with adults with CP and T2DM without GLP-1 receptor agonist exposure. The cohort-definition pages identified 6,782 exposed patients and 71,643 controls; the TriNetX matching module reported 6,785 and 71,665 patients before matching. After 1:1 nearest-neighbor propensity score matching, 6,569 patients remained in each cohort. Outcomes were assessed from 1 day to 1,095 days after index and analyzed using risk-based measures and Kaplan-Meier time-to-event methods.Results GLP-1 receptor agonist use was associated with lower hazards of several key pancreatic outcomes ( IDDF2026-ABS-0342 Figure 1. Forest plot for hazard ratio of clinical outcomes), including exocrine pancreatic insufficiency (181/6,134 [3.0%] vs 315/6,078 [5.2%]; hazard ratio [HR] 0.611, 95% CI 0.508-0.733), recurrent acute pancreatitis (189/3,631 [5.2%] vs 335/3,410 [9.8%]; HR 0.551, 95% CI 0.461-0.659), and pancreatic cancer (132/6,253 [2.1%] vs 273/6,069 [4.5%]; HR 0.481, 95% CI 0.390-0.592). All-cause mortality was also lower (487/6,540 [7.4%] vs 1,055/6,536 [16.1%]; HR 0.501, 95% CI 0.450-0.558), as were emergency room visits (HR 0.825), hospitalization (HR 0.747), composite gastrointestinal cancers (HR 0.586), chronic opioid prescriptions (HR 0.629) (IDDF2026-ABS-0342 Figure 2. Event rates), endoscopic pancreatic interventions (HR 0.551), major pancreatic surgery for CP (HR 0.514), and multiple biliary outcomes including ERCP (HR 0.456). Endocrine pancreatic insufficiency was lower on risk analysis but not on time-to-event analysis (HR 0.926, 95% CI 0.789-1.086). DKA/HHS and gastroparesis were not significantly different. Across 42 prespecified matched outcomes, 32 showed significantly lower hazard in the GLP-1 receptor agonist cohort, 2 were lower on risk analysis alone, 7 showed no significant difference, and vitamin D deficiency was the only outcome with a higher hazard (HR 1.180, 95% CI 1.027-1.355).Conclusions In this study of adults with CP and T2DM, GLP-1 receptor agonist use was associated with lower risks of pancreatic disease progression, healthcare utilization, several CP-directed interventions, and all-cause mortality, without a significant increase in DKA/HHS or gastroparesis.Abstract IDDF2026-ABS-0342 Figure 1Abstract IDDF2026-ABS-0342 Figure 2",
  "authors": [
    {
      "affiliations": [
        "Barasat Government Medical College and Hospital, India"
      ],
      "name": "Jyotirmoy Biswas"
    },
    {
      "affiliations": [
        "Roswell Park Comprehensive Cancer Center, United States"
      ],
      "name": "Fayaz Khan"
    },
    {
      "affiliations": [
        "Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom"
      ],
      "name": "Arkadeep Dhali"
    }
  ],
  "title": "IDDF2026-ABS-0342 Clinical outcomes associated with GLP-1 receptor agonists in patients with chronic pancreatitis and type 2 diabetes mellitus: a real world cohort study",
  "uid": "dfdeec6f-4051-56dd-a859-76ac40970755"
}